Researchers of a study looked at psychosis, characterized by delusions and hallucinations, and its prevalence in the majority of patients with Alzheimer’s disease (AD), significantly affecting their cognitive decline and dependence. These symptoms are persistent and often recur even after short-term resolution. The presence of psychotic symptoms in patients with AD is linked to a faster cognitive decline.

Genetic factors play a significant role in the development of psychosis in AD, with evidence pointing toward various genetic and neurochemical associations. The presence of psychosis in patients with AD is associated with faster cognitive and functional decline, more rapid institutionalization, and increased mortality. Despite the urgent need for effective treatment, there are no licensed therapies specifically for AD psychosis, although current research is exploring potential neurobiological mechanisms and trialing various pharmacological and non-pharmacological treatments.

Reference: Ballard C, Kales HC, Lyketsos C, et al. Psychosis in Alzheimer’s Disease. Curr Neurol Neurosci Rep. 2020;20(12):57. doi: 10.1007/s11910-020-01074-y.